Scarica l'app Stockscreener
7.03
1.40%
-0.10
Dopo l'orario di chiusura:
7.25
0.22
+3.13%
Precedente Chiudi:
$7.13
Aprire:
$7.08
Volume 24 ore:
199.68K
Relative Volume:
0.42
Capitalizzazione di mercato:
$11.14M
Reddito:
-
Utile/perdita netta:
$-14.58M
Rapporto P/E:
-6.113
EPS:
-1.15
Flusso di cassa netto:
$-9.80M
1 W Prestazione:
-5.51%
1M Prestazione:
+68.59%
6M Prestazione:
-8.73%
1 anno Prestazione:
-82.85%
Intervallo 1D:
$6.7601
$7.35
Intervallo di 1 settimana:
$6.75
$7.98
Portata 52W:
$3.80
$41.00
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Nome
Acurx Pharmaceuticals Inc
Settore
Industria
Telefono
917-533-1469
Indirizzo
259 LIBERTY AVENUE, STATEN ISLAND
Confronta ACXP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
7.03 | 12.03M | 0 | -14.58M | -9.80M | -1.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Acurx Pharmaceuticals Inc Borsa (ACXP) Ultime notizie
Can Acurx Pharmaceuticals Inc. (3ZO) stock test all time highsChart Signals & High Win Rate Trade Alerts - newser.com
Will Acurx Pharmaceuticals Inc. stock split attract more investorsJuly 2025 PostEarnings & Consistent Return Investment Signals - newser.com
Quantitative breakdown of Acurx Pharmaceuticals Inc. recent moveWeekly Market Summary & Momentum Based Trading Ideas - newser.com
What Fibonacci levels say about Acurx Pharmaceuticals Inc. reboundWeekly Investment Recap & Reliable Breakout Forecasts - newser.com
How Acurx Pharmaceuticals Inc. (3ZO) stock reacts to fiscal policiesMarket Risk Report & Capital Efficiency Focused Ideas - newser.com
Can Acurx Pharmaceuticals Inc. stock attract ESG capital inflows2025 Breakouts & Breakdowns & Verified Entry Point Detection - newser.com
Can swing trading help recover from Acurx Pharmaceuticals Inc. lossesTrade Entry Summary & Real-Time Buy Zone Alerts - newser.com
Why retail investors favor Acurx Pharmaceuticals Inc. stockWeekly Risk Report & High Conviction Trade Alerts - newser.com
Multi factor analysis applied to Acurx Pharmaceuticals Inc.2025 Valuation Update & Real-Time Stock Movement Alerts - newser.com
Acurx Pharmaceuticals Inc.’s volatility index tracking explainedMarket Volume Summary & Weekly Momentum Stock Picks - newser.com
New to The Street Broadcasts Tonight on Bloomberg Featuring Roadzen, Metaterra, NRx Pharma, Blackbarn NYC, and Humanitarian Travel Group - Kansas City Star
Acurx Pharmaceuticals (NASDAQ:ACXP) Raised to Hold at Wall Street Zen - Defense World
Acurx Pharmaceuticals granted Australian patent for antibiotics - Investing.com Australia
Acurx Pharmaceuticals granted Australian patent for antibiotics By Investing.com - Investing.com Nigeria
Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors - Stock Titan
Measuring Acurx Pharmaceuticals Inc.’s beta against major indicesJuly 2025 Levels & Verified Swing Trading Watchlist - newser.com
Xenetic Biosciences (XBIO) Stock Skyrockets – Is the Biotech’s 2025 Rally for Real? - ts2.tech
What drives Acurx Pharmaceuticals Inc stock pricePrice-to-Earnings Ratio Insights & High Return Market Tips - earlytimes.in
Pharma Boom: Acurx on the Rise - StocksToTrade
ACXP’s Steady Climb: New Developments? - timothysykes.com
90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions - ts2.tech
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Resigns with New to The Street for Long-Form Interviews, National TV Commercials, Earned Media, and Accredited Investor Events - Corpus Christi Caller-Times
Will breakout in Acurx Pharmaceuticals Inc. lead to full recoveryPortfolio Update Summary & Daily Technical Stock Forecast Reports - newser.com
Acurx Pharmaceuticals Inc Stock Analysis and ForecastInterest Rate Changes & Build Capital Safely - earlytimes.in
How supply shortages influence Acurx Pharmaceuticals Inc. (3ZO) stockInsider Buying & Weekly Stock Performance Updates - newser.com
Acurx Pharmaceuticals Inc. stock trendline breakdownChart Signals & Long-Term Investment Growth Plans - newser.com
Will Acurx Pharmaceuticals Inc. stock outperform Nasdaq indexJuly 2025 Earnings & Precise Buy Zone Identification - newser.com
New to The Street to Broadcast Nationwide on Bloomberg Tonight at 6:30 PM EST - Tacoma News Tribune
Acurx Pharmaceuticals (NASDAQ:ACXP) Lowered to Sell Rating by Wall Street Zen - Defense World
Will Acurx Pharmaceuticals Inc. (3ZO) stock return to pre crash levels2025 Price Action Summary & Comprehensive Market Scan Insights - newser.com
Chart overlay techniques for tracking Acurx Pharmaceuticals Inc.2025 Support & Resistance & Consistent Profit Alerts - newser.com
Acurx Pharmaceuticals stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
Acurx Pharmaceuticals stock maintains Buy rating at H.C. Wainwright - Investing.com
EMA approves Acurx’s pediatric plan for C. difficile drug ibezapolstat By Investing.com - Investing.com Nigeria
Acurx Pharmaceuticals (NASDAQ:ACXP) Given “Buy” Rating at HC Wainwright - Defense World
H.C. Wainwright Maintains Acurx Pharmaceuticals(ACXP.US) With Buy Rating, Maintains Target Price $31 - 富途牛牛
Promising Outlook for Acurx Pharmaceuticals: Buy Rating Driven by Regulatory Milestones and Clinical Success of Ibezapolstat - TipRanks
EMA approves Acurx’s pediatric plan for C. difficile drug ibezapolstat - Investing.com
Acurx Pharmaceuticals Inc Azioni (ACXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Acurx Pharmaceuticals Inc Azioni (ACXP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sailer Carl | Director |
Jan 06 '25 |
Buy |
1.01 |
24,631 |
25,000 |
137,183 |
| LUCI DAVID P | President and CEO |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,097,458 |
| Donohue James J. | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
22,352 |
| DELUCCIA ROBERT J | Director |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,010,196 |
| DEAN JACK H | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
21,776 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):